Latest News
PerkinElmer to Acquire BioLegend in Deal Valued at USD 5.25bn
Tuesday 27 July 2021

Massachusetts, US-based sciences and healthcare services provider PerkinElmer, Inc. (NYSE: PKI) has agreed to acquire California-based life science antibodies and reagents provider BioLegend, for approximately USD 5.25bn, in a combination of cash and stock, the company said.

BioLegend provides its academic and biopharmaceutical customers with antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.

The transaction will be the largest in PerkinElmer's history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.

Upon joining PerkinElmer, BioLegend will expand PerkinElmer's existing life science franchise into new segments, and its campus in San Diego, California will become PerkinElmer's global Centre of Excellence for research reagent content development for the combined company.

Goldman Sachs and Co. LLC, Inc., is serving as exclusive financial advisor to PerkinElmer, with WilmerHale serving as legal counsel and McDermott Will and Emery serving as antitrust counsel. J.P. Morgan Securities LLC is serving as exclusive financial advisor to BioLegend with Pillsbury Winthrop Shaw Pittman LLP serving as legal counsel.
Date Published: 27/07/2021